Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial

Incyte has laid down a marker in its pursuit of Regeneron and Sanofi’s Dupixent in prurigo nodularis, linking its oral challenger to significant improvements in itch and disease severity in a phase 2 study.